Perspective Therapeutics (CATX) said Tuesday it has treated the first patient in a phase 1/2a dose-finding trial to evaluate the safety and initial anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha.

Patient selection is based on single-photon emission computed tomography, or SPECT imaging using [203Pb]PSV359, the company said.

Fibroblast activation protein alpha is a protein commonly found on the surface of cancer-associated fibroblasts in the stroma, a component of the tumor microenvironment in most epithelial cancers, the company said.

Shares of Perspective Therapeutics were down more than 2% in recent Tuesday trading.

Price: 2.40, Change: -0.06, Percent Change: -2.24